Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
FDA approves leucovorin for rare autism-linked condition, pending further research.
The FDA has approved leucovorin, a form of folate, for treating cerebral folate deficiency, a rare condition linked to autism-like symptoms, based on limited clinical evidence.
While not a cure for autism spectrum disorder, early studies suggest leucovorin may improve communication, social skills, and behavior in some children with specific biological markers such as folate receptor autoantibodies or genetic issues affecting folate processing.
The drug, already used for anemia and chemotherapy side effects, is being explored off-label for autism, but experts caution that evidence remains limited and inconsistent across small trials.
The approval, made by GlaxoSmithKline and announced on September 22, 2025, reflects growing interest in targeted treatments for neurodevelopmental conditions, though larger, long-term research is needed to confirm safety and effectiveness.
Health officials emphasize the importance of individualized medical evaluation before use.
La FDA aprueba la leucovorina para una rara condición relacionada con el autismo, a la espera de más investigación.